114 related articles for article (PubMed ID: 15047202)
21. Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs.
Shen C; Zhang J; Xia L; Meng F; Xie W
Cell Immunol; 2007 May; 247(1):28-35. PubMed ID: 17720150
[TBL] [Abstract][Full Text] [Related]
22. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
23. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
24. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.
Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128
[TBL] [Abstract][Full Text] [Related]
25. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
26. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.
Boesen A; Sundar K; Coico R
Clin Diagn Lab Immunol; 2005 Oct; 12(10):1223-30. PubMed ID: 16210487
[TBL] [Abstract][Full Text] [Related]
27. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
[TBL] [Abstract][Full Text] [Related]
28. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
30. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
[TBL] [Abstract][Full Text] [Related]
31. Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses.
Caserta S; Alessi P; Guarnerio J; Basso V; Mondino A
Cancer Res; 2008 Apr; 68(8):3010-8. PubMed ID: 18413771
[TBL] [Abstract][Full Text] [Related]
32. Artificial antigen-presenting cells: artificial solutions for real diseases.
Oelke M; Krueger C; Giuntoli RL; Schneck JP
Trends Mol Med; 2005 Sep; 11(9):412-20. PubMed ID: 16103011
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
[TBL] [Abstract][Full Text] [Related]
34. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
35. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
Ding W; Fong C
Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
[TBL] [Abstract][Full Text] [Related]
36. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
37. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
[TBL] [Abstract][Full Text] [Related]
38. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
39. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
Santegoets SJ; Schreurs MW; Masterson AJ; Liu YP; Goletz S; Baumeister H; Kueter EW; Lougheed SM; van den Eertwegh AJ; Scheper RJ; Hooijberg E; de Gruijl TD
Cancer Immunol Immunother; 2006 Dec; 55(12):1480-90. PubMed ID: 16468034
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]